Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03570749 · OUTCOME

Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Week 52

What was measured

PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

Analysis population: All randomized phase 3 open-label addendum participants with baseline PRO for scalp hair assessment of ≥ 3 and who had evaluable data for this outcome measure.

Groups in this outcome

4 mg Baricitinib Phase 3 Open-Label Addendum

Participants who received one 4 mg Baricitinib tablet administered orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
4 mg Baricitinib Phase 3 Open-Label Addendum10

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
4 mg Baricitinib Phase 3 Open-Label Addendum20.0Not reported5.751.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.7
        upper Limit
        51.0
        value
        20.0
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received one 4 mg Baricitinib tablet administered orally QD.
    id
    OG000
    title
    4 mg Baricitinib Phase 3 Open-Label Addendum
param Type
NUMBER
population Description
All randomized phase 3 open-label addendum participants with baseline PRO for scalp hair assessment of ≥ 3 and who had evaluable data for this outcome measure.
reporting Status
POSTED
time Frame
Week 52
title
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice